Approaching tolerance in transplantation

International Archives of Allergy and Immunology

Volumn 126, Issue 1, 2001, Pages 11-22

  Waldmann, Herman ^a   Cobbold, Stephen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Deletion; Haemopoietic chimerism; Infectious tolerance; T cells, regulatory; Tolerance; Transplantation

Indexed keywords

ANTIBODY; ANTIGEN; CD4 ANTIGEN; DRUG; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL STIMULATION; CHIMERA; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HELPLESSNESS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MAINTENANCE THERAPY; MEDICAL RESEARCH; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SHORT COURSE THERAPY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHIMERA; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; MICE; MODELS, BIOLOGICAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034779986     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049490     Document Type: Review

References (123)

1. Acquired immunological tolerance to foreign cells
2. Tolerance, danger, and the extended family
3. Danger signals SOS to the immune system
4. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo
5. Differentiation of T regulatory cells by immature dendritic cells
6. The induction of tolerance by dendritic cells that have captured apoptotic cells
7. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
8. Requirement of the chemokine receptor CXCR3 for acute allograft rejection
9. Chemokines and their receptors in allograft rejection
10. Use of allogeneic, homozygous bone marrow cells for induction of specific immunological tolerance in mice treated with anti-lymphocyte serum
11. Antilymphocyte serum, donor bone marrow and tolerance to allografts: The journey is the reward
12. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG
13. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
14. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
15. Therapy with monoclonal antibodies. Elimination of T-cell subsets in vivo
16. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: The depletion of T-cell subsets in vitro and in vivo
17. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
18. Mixed chimerism and transplant tolerance
19. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
20. Interaction of rat monoclonal antibodies with human killer cells
21. Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes
22. Immunoglobulin heavy chain locus of the rat: Striking homology to mouse antibody genes
23. Isolation of low-frequency class-switch variants from rat hybrid myelomas
24. Reshaping human antibodies for therapy
25. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
26. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
27. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
28. New strategies for bone marrow transplantation
29. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
30. Tolerance of rat monoclonal antibodies: Implications for serotherapy
31. Induction of tolerance by monoclonal antibody therapy
32. Induction of immune tolerance by administration of monoclonal antibody to L3T4
33. Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4
34. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4 cells
35. Mechanisms of monoclonal antibody-facilitated tolerance inductionA possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination
36. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction
37. Treatment of murine lupus with F(ab')2 fragments of monoclonal anti-body to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion
38. Induction of tolerance in peripheral T cells with monoclonal antibodies
39. Tolerance induction in the peripheral immune system
40. Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets
41. Islet allograft survival after a single course of treatment of recipient with antibody to L3T4
42. Induction of classical transplantation tolerance in the adult
43. Classical transplantation tolerance in the adult. The interaction between myeloablation and immunosuppression
44. Monoclonal antibody therapy for the prevention of graft-vs.-host disease
45. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen
46. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: Requirement for chimerism to maintain tolerance
47. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation
48. Chimerism and central tolerance
49. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance
50. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
51. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death
52. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
53. Tolerance induction by 'megadose' transplants of CD34+ stem cells: A new option for leukemia patients without an HLA-matched donor
54. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
55. Bone marrow transplantation induces either clonal deletion or infectious disease tolerance depending on the dose
56. The induction of skin graft tolerance in MHC-mismatched or primed recipients: Primed T-cells can be tolerized in the periphery with CD4 and CD8 antibodies
57. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies
58. Tolerance in the mouse to MHC mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8
59. Mechanisms of induction of tolerance to organ allografts
60. Induction of infectious tolerance to MHC incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients
61. Mechanisms in CD4 antibody-mediated transplantation tolerance: Kinetics of induction, antigen dependency and role of regulatory T cells
62. Linked suppression can operate through indirect recognition
63. 'Infectious' transplantation tolerance
64. T cell regulation in adult transplantation tolerance
65. T-cell suppression in transplantation tolerance through linked recognition
66. Tolerance and suppression in a primed immune system
67. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8
68. CD4+ suppressor cells block allotransplant rejection
69. Amplification of natural regulatory immune mechanisms for transplantation tolerance
70. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
71. What is the role of regulatory T cells in transplantation tolerance
72. Regulating the immune response to transplants: A role for CD4+ regulatory cells?
73. IL-10 is required for regulatory T-cells to mediate tolerance to alloantigens in vivo
74. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model
75. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
76. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
77. Transplantation tolerance induced by CTLA4-Ig
78. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance
79. Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice
80. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
81. The CD28/B7 system of T-cell costimulation
82. Coexistence of Th1- and Th2-type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance
83. The in vivo mechanism of action of CTLA-4Ig
84. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4
85. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA-4 Fc treatment
86. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4
87. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression
88. Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance
89. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long-term engraftment and tolerance in stringent transplant models
90. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
91. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
92. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
93. A theoretical framework for self-tolerance and its relevance to therapy of autoimmune disease
94. Activation vs tolerance. A decision made by T-helper cells
95. In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help
96. A fail-safe mechanism for maintaining self-tolerance
97. Monoclonal antibodies as agents to reinduce tolerance in immunity
98. Impaired alloantigen mediated T cell apoptosis and failure to induce long term allograft survival in IL-2 deficient mice
99. The role of T cell apoptosis in transplantation tolerance
100. T-cell death and transplantation tolerance
101. Blocking the common gamma chain of cytokine receptors induces T cell apoptosis and long term islet allograft survival
102. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells
103. Immune regulation by CD40 and its ligand GP39
104. How may immunosuppression lead to tolerance? The war analogy
105. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFKB: Implications for tolerance induction
106. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys
107. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
108. Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9
109. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression
110. Tolerance to vascularised organ allografts in large-animal models
111. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression
112. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin
113. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
114. T cell depletion as a means of achieving tolerance
115. Durable donor-specific T and B-cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: Absence of chronic allograft nephropathy
116. Mixed chimerism and tolerance without whole body irradiation in a large animal model
117. Knowledge about transplantation tolerance gained in primates
118. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin
119. Anti-CD154 monoclonal antibody and thromboembolism
120. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
121. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft patients
122. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
123. Infectious immunological tolerance